Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 3/2013

01-03-2013 | Letter to the Editor

Distinct efficacy of pegylated-interferon α2a and α2b during treatment of essential thrombocythemia

Authors: Nicolas Noel, Jean-Marie Michot, Caroline Besson, Cécile Goujard, Olivier Lambotte

Published in: International Journal of Hematology | Issue 3/2013

Login to get access

Excerpt

To the Editor, …
Literature
1.
Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27:5418–24.PubMedCrossRef
2.
Alvarado Y, Cortes J, Verstovsek S, Thomas D, Faderl S, Estrov Z, et al. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol. 2003;51:81–6.PubMedCrossRef
3.
Bruno R, Sacchi P, Cima S, Maiocchi L, Novati S, Filice G, et al. Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles. J Viral Hepat. 2012;19(Suppl 1):33–6.PubMedCrossRef
4.
Moll HP, Maier T, Zommer A, Lavoie T, Brostjan C. The differential activity of interferon-α subtypes is consistent among distinct target genes and cell types. Cytokine. 2011;53:52–9.PubMedCrossRef
5.
Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology. 2010;51:1176–84.PubMedCrossRef
6.
Wang Q, Miyakawa Y, Fox N, Kaushansky K. Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood. 2000;96:2093–9.PubMed
Metadata
Title
Distinct efficacy of pegylated-interferon α2a and α2b during treatment of essential thrombocythemia
Authors
Nicolas Noel
Jean-Marie Michot
Caroline Besson
Cécile Goujard
Olivier Lambotte
Publication date
01-03-2013
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2013
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-013-1288-x

Other articles of this Issue 3/2013

International Journal of Hematology 3/2013 Go to the issue

Original Article

Prognostic value of Waldeyer’s ring involvement of diffuse large B-cell lymphoma treated with R-CHOP

Case Report

Diffuse panbronchiolitis after humanized anti-CCR4 monoclonal antibody therapy for relapsed adult T-cell leukemia/lymphoma

Original Article

Risk factors influencing mortality related to Stenotrophomonas maltophilia infection in hematology–oncology patients

Original Article

Chronic lymphocytic leukemia in Korean patients: frequent atypical immunophenotype and relatively aggressive clinical behavior

Images in Hematology

Hypopyon as the first sign of relapse in acute lymphoblastic leukaemia

Letter to the Editor

Acute abdomen due to splenic infarction as the initial presentation of pediatric acute lymphoblastic leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits